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Abstract 
Alpha-Galactosyl Ceramide (α-GalCer) is a prototypical synthetic ligand of invariant natural 
killer T (iNKT) cells. Upon presentation by the MHC class I-like molecule CD1d, this 
glycolipid stimulates iNKT cells to secrete a vast amount of both pro-inflammatory Th1 and 
anti-inflammatory Th2 cytokines. Recently, we discovered that selected 6”-modified α-
GalCer analogues may produce markedly Th1-biased responses due to the formation of either 
an additional anchor with CD1d or by establishing extra interactions with the T-cell receptor 
of iNKT cells. Here, we report a practical synthesis towards 6”-O-carbamate and 
galacturonamide analogues of α-GalCer and their evaluation as iNKT cell agonists in mice.  
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Introduction 
α-GalCer or KRN7000 (1, Figure 1) is a synthetic glycolipid derived from a group of 
galactosylceramides found in marine sponge extracts showing promising anti-tumor activity 
in a B16-melanoma murine model and currently under investigation in different early phase 
human trials for patients with metastatic cancer.1,2 α-GalCer is the prototypical antigen for 
iNKT-cells, a subset of T-lymphocytes, which show features of both innate and adaptive 
immunity. Whereas conventional T-cells are activated by recognition of peptide antigens 
presented by MHC class I or II molecules, iNKT-cells recognize lipid and glycolipid antigens 
in the context of CD1d expressed on antigen presenting cells.3,4 CD1d shows striking 
structural analogy with the MHC class I protein,5 however, it comprises a deeper and more 
lipophilic binding groove in line with the differences in antigen presentation. Indeed, crystal 
structures of both mouse and human CD1d bound to α-GalCer show that the lipid chains of α-
GalCer are accommodated in two hydrophobic pockets. The F’ pocket binds the 
phytosphingosine chain while the fatty acyl chain fills the A’ pocket. As a result the galactose 
sugar is oriented towards the surface of CD1d, available for recognition by the TCR of iNKT 
cells.6,7 
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Figure 1. Structures of KRN7000 (1), OCH (2) and α-C-GalCer (3) 
 
Engagement of the CD1d-α-GalCer complex by the TCR of iNKT cells results in a rapid 
production of Th1 and Th2 cytokines both by iNKT cells itself and by activation of bystander 
immune cells.8 The robust cytokine production shows promise for a broad range of 
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therapeutic applications, but despite its potent immune response α-GalCer showed limited 
therapeutic outcome in the clinic.9,10 The concomitant release of both Th1 and Th2 cytokines, 
which have opposing effects in vivo, is believed to account for its poor efficacy. Indeed, α-
GalCer analogues capable of skewing the cytokine profile have improved therapeutic 
potential.11,12, 13 OCH (2), characterized by a truncated phytosphingosine chain, improves 
disease in animal models of experimental autoimmune encephalitis and arthritis as a result of 
a Th2 biased cytokine secretion.14,15 Stabilizing the anomeric bond by substituting a 
methylene unit for the glycosidic oxygen gave rise to α-C-GalCer (3), a compound with a 
marked Th1 response and superior malaria protection in mice.16 
Modifications of the galactose moiety are mostly focusing on the 6”-position,17,18 as other 
alterations generally result in poor antigenicity. Previously, we discovered that a C-6”-
naphthylurea derivative (NU-α-GalCer, 4, Figure 2) induces a potent Th1 response both in a 
murine and a human setting resulting in a superior tumor protection in the B16 mouse 
melanoma model.19 Crystallographic studies of the ternary CD1d-NU-α-GalCer-TCR 
complex revealed that the naphthyl moiety occupies a narrow binding pocket in CD1d above 
the A’ roof by induced fit, thereby enhancing the affinity for CD1d. The latter led us to 
investigate other modifications at the C-6” position. Here we describe the synthesis of a series 
of C-6”-carbamate and C-5”-uronamide derivatives. 
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Figure 2. Structures of NU-α-GalCer (4), C-6”-carbamate (5) and C-5”-uronamide 
derivatives (6) of α-GalCer 
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Results and Discussion 
Chemistry 
Both the C-6”-carbamates 5a-5c and the C-5”-amides 6a-6g can be accessed from the 
common intermediate 8, which is swiftly obtained upon treatment of the 4,6-benzylidene 
precursor with Cu(OTf)2 and BH3.THF. We previously started from the same intermediate for 
the synthesis of galacturonic acid and 6”-triazole analogues of α-GalCer.20,21 The primary OH 
group of 8 was converted into carbamates 9a and 9b upon reaction with the appropriate 
isocyanate, while compound 9c was obtained by treating 8 with 4-aminopyridine and 1,1’-
carbonyldiimidazole (CDI).  
The synthesis of the uronamides 11a-11g commenced with the TEMPO/BAIB oxidation of 
the primary hydroxyl group of 8 to afford the galacturonic acid intermediate 10.21 Successive 
coupling with the appropriate amine in the presence of 2-(6-chloro-1-H-benzotriazole-1-yl)-
1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU) gave access to amides 11a-g. 
Palladium-catalyzed hydrogenation furnished the desired carbamates 5a-5c and amides 6a-6e. 
However, this deprotection method failed to remove the benzyl protecting groups of the 
sulfur-containing compound 11f, even under high pressure (50 bar), while overreduction of 
the naphthyl moiety was observed during hydrogenation of intermediates 9b and 11g. In case 
of naphthyl carbamate 9b, careful monitoring of the reaction yet allowed obtaining the final 
product. For the naphthyl amide compound, however, undesired reduction of the naphthyl 
ring was observed before all benzyl groups were removed, thereby impeding isolation of the 
envisaged analogue. This led us to explore alternative deprotection conditions for compounds 
11f and 11g. Treatment with aluminum chloride and dimethylaniline allowed to produce the 
desired products 6f and 6g, albeit in low yields. 
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Scheme 1. Reagents and conditions. (a) i. RNCO, DMF, 67%-74% or ii. RNH2, CDI, DMF, 
70 °C, 33%; (b) Pd black, H2, EtOH/CHCl3, 49%-86%; (c) TEMPO, BAIB, CH2Cl2/H2O, 
87%; (d) RNH2, HCTU, DIPEA, DMF, 53%-87 %; (e) AlCl3, dimethylaniline, CH2Cl2, 
11%-15%. 
 
Biological Evaluation 
The biological activity of all target glycolipids was assessed by measuring IFN-γ and IL-4 
serum levels after intraperitoneal injection of 5 μg in mice (Figure 3). Except for 6a and 6f, 
the C-5”-amides are generally weaker antigens than α-GalCer with a Th1 cytokine bias, 
mainly originating from significantly lower IL-4 levels compared to α-GalCer.  
The C-6”-carbamates clearly exhibit stronger antigenic effects than the uronamides, but their 
cytokine profiles resemble that of α-GalCer. 
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 Figure 3. IFN-γ and IL-4 secretion, measured at respective 16 h and 4 h, after intraperitoneal 
injection of 5 μg of the glycolipids in mice (glycolipids were tested in at least 2 different 
experiments with 5-8 mice per group for each glycolipid).  
It was shown that the remarkably high INF-γ release of the C-6”-carbamates (5a-c) stems 
from a higher APC-derived IL-12 production, compared with that of α-GalCer.22 Notable, 
high IL-12 secretion was observed with 5c, largely exceeding that induced by NU-α-GalCer. 
The crystal structure of the ternary mCD1d-5b-TCR complex indicates that the binding mode 
of 5b in the parallels that of NU-α-GalCer. In particular, its naphthylcarbamate moiety also 
induces a hydrophobic pocket in CD1d by displacement of Met69 (Figure 4),23 indicating that 
the naphthyl moiety drives the observed induced fit rather than the nature of the linker, given 
that the length of the latter is appropriate. Probably, this extra interaction with CD1d 
compensates for the observed loss of the hydrogen bond between the 4”-OH group and Asn-
30 of the TCR. Although the in vivo data indicate that 5b is a potent antigen, at present we 
have no explanation for its distinct cytokine profile compared to NU-α-GalCer.  
Previously, compound 5c (PyrC-α-GalCer) was shown to be tilted towards the TCR thereby 
forming intimate contacts with the TCR instead of forming a third anchor inside CD1d. The 
carbamate moiety of 5a, on the other hand, was situated laterally above the CD1d binding 
group, suggesting that the smaller pyridine as well as the phenyl ring are not sufficient to 
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induce the structural change within the A’ roof of CD1d, in contrast to both 5b and NU-α-
GalCer, which have the larger naphthyl ring. 
 
Figure 4. Crystal structure of 5b bound to CD1d, compared with that of NU-α-GalCer. 
 
Conclusions 
In summary, we have synthesized a series of C-6”-carbamate and C-5”-galacturonamide 
derivatives of α-GalCer from a common intermediate 8, further illustrating the highly 
convergent potential of the latter. Generally, the antigenic potency of the carbamates is 
superior to that of the uronamides, although within each series significant variations in 
cytokine profiles are observed depending on the substitution patterns.  
The binding behavior of the naphthylcarbamate 5b in the ternary complex is strikingly similar 
to that of NU-α-GalCer (4). The naphthyl moiety of both analogues occupies an extra binding 
pocket in CD1d. Determinants for the induction of this hydrophobic pocket possibly involve 
the size of the aromatic group and the correct positioning of a carbonyl that acts as H-bond 
acceptor. By varying the carbamate substituents it may be possible to increase the interaction 
with either the TCR or CD1d. A notable advantage of the carbamate derivatives over their 
urea analogues is that the synthesis of the former is significantly shorter. 
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Experimental Section 
Chemical Synthesis 
General  
Precoated Macherey-Nagel SIL G/UV254 plates were used for TLC, and spots were 
examined under UV light at 254 nm and further visualized by sulfuric acid-anisaldehyde 
spray. Column chromatography was performed on Biosolve silica gel (32 - 63 µm, 60 Å). 
NMR spectra were obtained with a Varian Mercury 300 Spectrometer. Chemical shifts are 
given in ppm (δ) relative to the residual solvent signals, in the case of CDCl3: δ = 7.26 ppm 
for 1H and δ = 77.4 ppm for 13C and in the case of pyridine-d5: δ = 8.74, 7.58 and 7.22 ppm 
for 1H and δ = 149.9, 135.5 and 123.5 ppm for 13C. Exact mass measurements were performed 
on a Waters LCT Premier XE TOF equipped with an electrospray ionization interface and 
coupled to a Waters Alliance HPLC system. Samples were infused in a CH3CN/HCOOH 
(1000/1) mixture at 10 mL/min. All melting points were determined on a Büchi B-545 
melting point apparatus and are uncorrected. 
Procedure for the synthesis of carbamates 9a and 9b  
To a solution of compound 8 (0.07 mmol) in DMF (1 mL) was added the appropriate 
isocyanate (0.18 mmol). After stirring overnight, the reaction mixture was evaporated to 
dryness under reduced pressure. Purification by column chromatography (hexanes/EtOAc: 
8/2) afforded carbamates 9a (74 %) and 9b (67 %).  
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-O-(4-chlorophenylcarbamoyl)-α-D-
galactopyranosyl)-2-(hexacosanamido)octadecane-1,3,4-triol (9a)  
1H NMR (300 MHz, CDCl3): δ 8.29 (s, 1H, NH), 7.31-7.10 (m, 29H, arom. H), 5.71 (d, J = 
6.6 Hz, 1H, NH), 4.88 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.79 (d, J = 3.9 Hz, 1H, H-1”), 4.75 (d, J 
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= 11.6 Hz, 1H, CH2-Ph), 4.67 (d, J = 12.0 Hz, 1H, CH2-Ph), 4.62 (d, J = 11.9 Hz, 1H, CH2-
Ph ), 4.61 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.57 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.52 (d, J = 11.4 
Hz, 1H, CH2-Ph), 4.51 ( d, J = 11.8 Hz, 1H, CH2-Ph), 4.42 (d, J = 11.6 Hz, 1H, CH2-Ph), 
4.41 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.33-4.26 (m, 2H, H-2, H-6”), 4.01-3.90 (m, 3H, H-2”, H-
1), 3.86-3.75 (m, 4H, H-3, H-3”, H-4”, H-5”), 3.69 (dd, J = 1.6 Hz and 11.4 Hz, 1H, H-6”), 
3.51-3.46 (m, 1H, H-4), 1.96-1.84 (m, 2H, COCH2), 1.58-1.06 (m, 72H, CH2), 0.77 (t, J = 6.9 
Hz, 6H, CH3). 
13C NMR (75 MHz, CDCl3): δ 173.93, 153.51, 138.79, 138.73, 138.69, 138.47, 138.22, 
137.63, 129.90, 128.96, 128.68, 128.64, 128.60, 128.57, 128.13, 128.04, 127.99, 127.90, 
127.84, 127.73, 127.66, 119.69, 100.52, 80.54, 79.72, 79.48, 77.67, 77.45, 77.25, 76.83, 
76.65, 75.20, 74.52, 73.88, 73.66, 73.62, 72.38, 70.26, 70.17, 65.87, 60.62, 52.34, 37.04, 
32.17, 32.16, 30.88, 29.97, 29.96, 29.94, 29.92, 29.89, 29.79, 29.61, 29.60, 29.48, 26.17, 
25.81, 22.93, 21.28, 14.43, 14.36.  
Exact mass (ESI-MS) for C92H133ClN2O10 [M+H]+ found, 1461.9786; calcd, 1461.9727.  
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-O-(1-naphthylcarbamoyl)-α-D-
galactopyranosyl)-2-(hexacosanamido)octadecane-1,3,4-triol (9b)  
1H NMR (300 MHz, pyridine-d5): δ 10.66 (s, 1H, NH), 8.99 (d, J = 8.4 Hz, 1H, NH), 8.84 (d, 
J = 8.4 Hz, 1H, arom. H), 8.37 (d, J = 7 Hz, 1H, arom. H), 7.96 (d, J = 7.9 Hz, 1H, arom. H), 
7.78 (d, J = 8.1 Hz, 1H, arom. H), 7.66-7.58 (m, 2H, arom. H), 7.55-7.29 (m, 26H, arom. H), 
5.43 (d, J = 3.4 Hz, 1H, H-1”), 5.17 (d, J = 11.1 Hz, 1H, CH2-Ph), 5.13 (d, J = 10.2 Hz, 1H, 
CH2-Ph), 5.00-4.82 (m, 4H, CH2-Ph, H-6”, H-2), 4.78-4.68 (m, 5H, H-6”, CH2-Ph), 4.64-
4.58 (m, 2H, H-5”, CH2-Ph ), 4.54 (dd, J = 2.0 and 8.4 Hz, 1H, H-3), 4.48-4.43 (m, 3H, H-1, 
H-2”, CH2-Ph), 4.34 (dd, J = 2.7 Hz and 10.2 Hz, 1H, H-3”), 4.25-4.20 (m, 2H, H-1, H-4”), 
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3.97-3.93 (m, 1H, H-4), 2.66-2.56 (m, 2H, COCH2), 2.15-1.18 (m, 72H, CH2), 0.90 (t, J = 6.7 
Hz, 3H, CH3), 0.89 (t, J = 6.4 Hz, 3H, CH3).  
13C NMR (75 MHz, pyridine-d5): δ 172.21, 154.34, 138.55, 138.41, 138.21, 138.12, 127.65, 
127.50, 127.29, 126.89, 126.80, 126.75, 126.58, 125.16, 125.11, 97.63, 80.00, 78.76, 77.89, 
76.09, 74.88, 73.94, 73.24, 72.26, 71.67, 70.70, 68.77, 61.38, 50.13, 49.97, 48.02, 38.95, 
35.66, 34.03, 30.97, 28.99, 28.87, 28.80, 28.74, 28.66, 28.43, 25.62, 25.27, 23.71, 21.78, 
13.12.  
Exact mass (ESI-MS) for C96H136N2O10 [M+H]+ found, 1478.0220; calcd, 1478.0273.  
Procedure for the synthesis of carbamate 9c  
To a solution of compound 8 (50 mg, 0.04 mmol) in DMF (0.5 mL) was added CDI (31 mg, 
0.18 mmol). After stirring overnight, the reaction mixture was heated until 70 °C and 4-
aminopyridine was added. The reaction mixture was stirred at 70 °C during 48 hours followed 
by evaporation to dryness under reduced pressure. Purification by column chromatography 
(hexanes/EtOAc: 7/3) afforded carbamate 9c (26 mg, 33 %). 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-O-(4-pyridinylcarbamoyl)-α-D-
galactopyranosyl)-2-(hexacosanamido)octadecane-1,3,4-triol (9c)  
1H NMR (300 MHz, CDCl3): δ 7.87 (s, 1H, NH), 7.35-7.15 (m, 28H, arom. H), 6.93 (s, 1H, 
arom. H), 5.69 (d, J = 8.2 Hz, 1H, NH), 4.90 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.81 (d, J = 3.7 
Hz, 1H, H-1”), 4.76 (d, J = 11.1 Hz, 1H, CH2-Ph), 4.73 (d, J = 11.3 Hz, 1H, CH2-Ph), 4.69 
(d, J = 11.3 Hz, 1H, CH2-Ph), 4.65 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.58 (d, J = 11.7 Hz, 1H, 
CH2-Ph), 4.55 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.48 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.40 (d, J = 
11.7 Hz, 1H, CH2-Ph), 4.39 (d, J = 11.5 Hz, 1H, CH2-Ph), 4.29-4.20 (m, 2H, H-2, H-6”), 
4.12-4.06 (m, 1H, H-6”), 3.99 (dd, J= 3.3 Hz and 9.8 Hz, 1H, H-2”), 3.94 (m, 1H, H-5”), 3.85 
(dd, J = 2.5 Hz and 10.1 Hz, 1H, H-3”), 3.81 (dd, J = 4.91 Hz and 11.0 Hz, 1H, H-1), 3.75 
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(app. s, 1H, H-4”), 3.68-3.64 (m, 1H, H-3), 3.62-3.56 (m, 1H, H-1), 3.48-3.43 (m, 1H, H-4), 
1.86-1.74 (m, 2H, COCH2), 1.54-1.09 (m, 72H, CH2), 0.83-0.76 (m, 6H, CH3).  
13C NMR (75 MHz, CDCl3): δ 173.09, 148.33, 138.68, 138.62, 138.52, 138.01, 137.32, 
130.68, 128.76, 128.73, 128.68, 128.66, 128.64, 128.60, 128.54, 128.16, 128.07, 128.05, 
127.97, 127.82, 127.78, 127.68, 117.33, 99.09, 80.11, 79.67, 79.13, 74.56, 73.83, 73.48, 
72.12, 68.33, 68.16, 66.68, 60.63, 56.66, 50.42, 36.97, 32.16, 31.82, 30.51, 30.04, 29.96, 
29.93, 29.89, 29.84, 29.67, 29.64, 29.60, 29.59, 26.02, 25.94, 22.92, 22.88, 21.27, 14.22, 
14.35.  
Exact mass (ESI-MS) for C91H133N3O10 [M+H]+ found, 1429.0229; calcd, 1429.0064.  
General procedure for the synthesis of amides (11a-11g)  
To a solution of 10 (150 mg, 0.11 mmol) in DMF (0.3 mL) and CH2Cl2 (0.7 mL) was added 
DIPEA (22 mg, 0.17 mmol). After stirring for 10 minutes at room temperature, HCTU (72 
mg, 0.17 mmol) was added and the mixture was stirred for 30 minutes. Then the appropriate 
amine (0.17 mmol) was added and the solution was continued stirring overnight. After 
completion of the reaction, the mixture was evaporated to dryness. The residue was 
partitioned between H2O and EtOAc and the aqueous layer was extracted with EtOAc. The 
organic layer was washed with brine and dried over Na2SO4. Purification by column 
chromatography (hexanes/EtOAc) and concentration under reduced pressure furnished the 
desired amides 11a (87 %), 11b (84 %), 11c (53 %), 11d (82 %), 11e (82 %), 11f (85 %) and 
11g (82 %).  
(2S,3S,4R)-(2,3,4-tri-O-benzyl-N-phenyl-α-D-galactopyranuronamidyl)-3,4-di-O-benzyl-
2-(hexacosanamido)octadecane-3,4-diol (11a)  
1H NMR (300 MHz, CDCl3): δ 8.20 (s, 1H, NH), 7.53 (d, J = 1.0 Hz, 2H, arom. H), 7.39-7.08 
(m, 28H, arom. H), 5.73 (d, J = 8.2 Hz, 1H, NH), 4.98 (d, J = 3.5 Hz, 1H, H-1”), 4.87 (d, J = 
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10.8 Hz, 1H, CH2-Ph), 4.84 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.79 (d, J = 12.7 Hz, 1H, CH2- 
Ph), 4.71 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.66 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.62 (d, J = 12.0 
Hz, 1H, CH2-Ph), 4.58 (d, J = 10.8 Hz, 1H, CH2-Ph), 4.55 (d, J = 11.6 Hz, 1H, CH2-Ph), 
4.51-4.45 (m, 3H, CH2-Ph and H-4”), 4.37 (app. d, J = 1.1 Hz, 1H, H-5”), 4.26 (m, 1H, H-2), 
4.07 (dd, J = 3.5 Hz and 10.1 Hz, 1H, H-2”), 3.98 (dd, J = 2.7 Hz and 10.0 Hz, 1H, H-3”), 
3.90-3.76 (m, 3H, H-1, H-3), 3.55-3.49 (m, 1H, H-4), 1.92- 1.78 (m, 2H, COCH2), 1.68-1.22 
(m, 72H, CH2), 0.88 (t, J = 6.7 Hz, 6H, CH3).  
13C NMR (75 MHz, CDCl3): δ 173.07, 166.69, 138.73, 138.70, 138.55, 138.50, 138.40, 
137.44, 129.16, 128.67, 128.65, 128.63, 128.61, 128.45, 128.35, 128.15, 128.07, 128.03, 
128.01, 127.92, 127.90, 127.81, 127.70, 124.76, 120.19, 99.21, 79.97, 79.20, 78.55, 76.63, 
76.10, 75.91, 74.10, 73.38, 72.72, 72.24, 72.14, 68.46, 50.19, 36.90, 32.16, 30.41, 30.05, 
29.96, 29.94, 29.89, 29.82, 29.65, 29.61, 29.60, 26.11, 25.85, 22.93, 14.36.  
Exact mass (ESI-MS) for C91H132N2O9 [M+Na]+ found, 1419.9889; calcd, 1419.9831.  
(2S,3S,4R)-(2,3,4-tri-O-benzyl-N-(3,4-dichlorophenyl)-α-D-galactopyranuronamidyl)-3,4-
di-O-benzyl-2-(hexacosanamido)octadecane-3,4-diol (11b)  
1H NMR (300 MHz, CDCl3): δ 8.17 (s, 1H, NH), 7.74 (d, J = 2.2 Hz, 1H, arom. H), 7.40-7.14 
(m, 27H, arom. H), 5.70 (d, J = 8.2 Hz, 1H, NH), 4.95 (d, J = 3.4 Hz, 1H, H-1”), 4.89-4.46 
(m, 11H, CH2-Ph and H-4”), 4.35 (d, J = 1.2 Hz, 1H, H-5”), 4.31-4.25 (m, 1H, H-2), 4.04 (dd, 
J = 3.4 Hz and 10.0 Hz, 1H, H-2”), 3.96 (dd, J = 2.6 Hz and 10.2 Hz, 1H, H-3”), 3.91 (dd, J = 
4.9 Hz and 10.6 Hz, 1H, H-1), 3.80-3.74 (m, 2H, H-1 and H-3), 3.56-3.52 (m, 1H, H-4), 1.94-
1.77 (m, 2H, COCH2), 1.60-1.08 (m, 72H, CH2), 0.88 (t, J = 6.7 Hz, 6H, CH3).  
13C NMR (75 MHz, CDCl3): δ 173.09, 167.17, 138.68, 138.66, 138.50, 138.43, 138.28, 
136.81, 132.93, 130.62, 128.70, 128.68, 128.65, 128.64, 128.42, 128.40, 128.11, 128.09, 
128.06, 128.01, 127.97, 127.94, 127.87, 127.70, 121.80, 119.37, 99.25, 79.92, 79.69, 78.49, 
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75.99, 74.11, 73.32, 72.94, 72.29, 68.67, 53.64, 50.20, 36.89, 32.16, 30.61, 30.05, 29.96, 
29.94, 29.91, 29.89, 29.82, 29.66, 29.61, 29.59, 26.12, 25.85, 22.92, 14.35.  
Exact mass (ESI-MS) for C91H130Cl2N2O9 [M+Na]+ found, 1487.9138; calcd, 1487.9046.  
(2S,3S,4R)-(2,3,4-tri-O-benzyl-N-benzyl-α-D-galactopyranuronamidyl)-3,4-di-O-benzyl-
2-(hexacosanamido)octadecane-3,4-diol (11c)  
1H NMR (300 MHz, CDCl3): δ 7.37-7.17 (m, 30H, arom. H), 6.79 (app. t, J = 5.9 Hz, 1H, 
NH), 5.74 (d, J = 8.1 Hz, 1H, NH), 4.88 (d, J = 3.7 Hz, 1H, H-1”), 4.85- 4.42 (m, 12H, CH2-
Ph, H-4”, NH-CH2), 4.35-4.28 (m, 2H, H-5” and NH-CH2), 4.26-4.18 (m, 1H, H-2), 4.04 (dd, 
J = 3.4 Hz and 9.9 Hz, 1H, H-2”), 3.95 (dd, J = 2.6 Hz and 10.0 Hz, 1H, H-3”), 3.82-3.71 (m, 
3H, H-1 and H-3), 3.49 (m, 1H, H-4), 1.93-1.78 (m, 2H, COCH2), 1.65-1.14 (m, 72H, CH2), 
0.87 (t, J = 6.6 Hz, 6H, CH3).  
13C NMR (75 MHz, CDCl3): δ 173.05, 168.75, 138.80, 138.76, 138.74, 138.51, 137.76, 
128.87, 128.63, 128.59, 128.40, 128.25, 128.15, 128.06, 128.01, 127.96, 127.87, 127.84, 
127.75, 127.67, 99.05, 80.00, 78.98, 78.61, 76.26, 76.03, 75.60, 74.04, 73.47, 72.59, 72.01, 
71.92, 68.18, 60.61, 50.12, 43.37, 36.88, 32.16, 31.82, 31.14, 30.27, 30.06, 29.96, 29.94, 
29.89, 29.84, 29.68, 29.61, 29.59, 26.16, 25.87, 22.92, 22.88, 14.43, 14.35.  
Exact mass (ESI-MS) for C92H134N2O9 [M+Na]+ found, 1433.9846; calcd, 1433.9982.  
(2S,3S,4R)-(2,3,4-tri-O-benzyl-N-(3,4-dichlorobenzyl)-α-D-galactopyranuronamidyl)-3,4-
di-O-benzyl-2-(hexacosanamido)octadecane-3,4-diol (11d)  
1H NMR (300 MHz, CDCl3): δ 7.38-7.22 (m, 26H, arom. H), 7.14 (d, J = 8.2 Hz, 1H, arom. 
H), 6.98 (dd, J = 1.9 Hz and 8.2 Hz, 1H, arom. H), 6.82 (t, J = 6.1 Hz, 1H, NH), 5.75 (d, J = 
8.0 Hz, 1H, NH), 4.92 (d, J = 3.3 Hz, 1H, H-1”), 4.89 (d, J = 11.0 Hz, 1H, CH2-Ph), 4.82 (d, J 
= 11.6 Hz, 1H, CH2-Ph), 4.79 (d, J = 12.1 Hz, 1H, CH2-Ph), 4.74 (d, J = 12.1 Hz, 1H, CH2-
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Ph), 4.72 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.65 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.56 (d, J = 11.6 
Hz, 1H, CH2-Ph), 4.55 (d, J = 11.0 Hz, 1H, CH2-Ph), 4.50-4.43 (m, 4H, CH2-Ph, NH-CH2 
and H-4”), 4.30-4.26 (m, 2H, H-5” and H-2), 4.20 (dd, J = 5.4 Hz and 15.1 Hz, 1H, NH-CH2), 
4.05 (d, J = 3.4 Hz and 10.1 Hz, 1H, H-2”), 3.96 (d, J = 2.5 Hz and 10.0 Hz, 1H, H-3”), 3.88-
3.73 (m, 3H, H-1 and H-3), 3.55-3.58 (m, 1H, H-4), 1.99-1.80 (m, 2H, COCH2), 1.72-1.16 
(m, 72H, CH2), 0.89 (t, J = 6.6 Hz, 6H, CH3).  
13C NMR (75 MHz, CDCl3): δ 173.06, 168.95, 138.73, 138.69, 138.50, 138.47, 138.24, 
132.72, 131.67, 130.87, 129.97, 128.66, 128.64, 128.62, 128.43, 128.13, 128.10, 128.03, 
127.96, 127.91, 127.84, 127.68, 127.33, 99.14, 79.96, 79.33, 78.60, 77.69, 77.27, 76.84, 
76.24, 75.98, 75.60, 74.06, 73.44, 72.73, 72.12, 71.97, 68.28, 50.18, 42.19, 36.91, 32.17, 
30.42, 30.06, 29.97, 29.95, 29.90, 29.85, 29.69, 29.62, 29.60, 26.15, 25.88, 22.94, 14.37.  
Exact mass (ESI-MS) for C92H132Cl2N2O9 [M+H]+ found, 1479.9365; calcd, 1479.9388.  
(2S,3S,4R)-(2,3,4-tri-O-benzyl-N-phenethyl-α-D-galactopyranuronamidyl)-3,4-di-O-
benzyl-2-(hexacosanamido)octadecane-3,4-diol (11e)  
1H NMR (300 MHz, CDCl3): δ 7.38-7.12 (m, 30H, arom. H), 6.61 (t, J = 6.0 Hz, 1H, NH), 
5.78 (d, J = 8.3 Hz, 1H, NH), 4.89 (d, J = 3.3 Hz, 1H, H-1”), 4.87 (d, J = 10.8 Hz, 1H, CH2-
Ph), 4.82 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.77 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.73 (d, J = 10.5 
Hz, 1H, CH2-Ph), 4.72 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.64 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.59 
(d, J = 10.8 Hz, 1H, CH2-Ph), 4.56 (d, J = 11.5 Hz, 1H, CH2-Ph), 4.51-4.49 (m, 1H, H-4”), 
4.48 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.46 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.27-4.29 (m, 2H, H-2 
and H-5”), 4.03 (dd, J = 3.5 Hz and 10.0 Hz, 1H, H-2”), 3.94 (dd, J = 2.7 Hz and 10.1 Hz, 1H, 
H-3”), 3.82 (dd, J = 2.9 Hz and 6.5 Hz, 1H, H-3), 3.79-3.71 (m, 2H, H-1), 3.53-3.45 (m, 3H, 
NH-CH2 and H-4), 2.73 (ddd, J = 7.2 Hz, 13.5 Hz and 28.0 Hz, 2H, CH2), 1.98-1.80 (m, 2H, 
COCH2), 1.65-1.19 (m, 72H, CH2), 0.88 (t, J = 6.8 Hz, 6H, CH3).  
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13C NMR (75 MHz, CDCl3): δ 172.99, 168.65, 138.88, 138.80, 138.77, 138.75, 138.53, 
138.51, 128.92, 128.78, 128.64, 128.62, 128.61, 128.39, 128.37,128.14, 128.06, 127.99, 
127.95, 127.88, 127.85, 127.70, 126.70, 98.97, 80.11, 78.92, 78.61, 77.68, 77.45, 77.25, 
76.83, 76.31, 76.03, 75.73, 74.06, 73.47, 72.53, 72.04, 71.81, 68.03, 50.11, 40.61, 36.91, 
36.03, 32.16, 30.29, 30.07, 29.97, 29.94, 29.92, 29.89, 29.85, 29.69, 29.64, 29.61, 29.60, 
26.21, 25.88, 22.93, 14.36.  
Exact mass (ESI-MS) for C93H136N2O9 [M+H]+ found, 1426.0337; calcd, 1426.0324 
(2S,3S,4R)-(2,3,4-tri-O-benzyl-N-(thiophen-3-ylmethyl)-α-D-galactopyranuronamidyl)-
3,4-di-O-benzyl-2-(hexacosanamido)octadecane-3,4-diol (11f)  
1H NMR (300 MHz, CDCl3): δ 7.30-7.13 (m, 25H, arom. H), 7.07 (dd, J = 1.4 Hz and 5.0 Hz, 
1H, arom. H), 6.81 (dd, J = 1.3 Hz and 3.4 Hz, 1H, arom. H), 6.79- 6.75 (m, 2H, arom. H and 
NH), 5.66 (d, J = 8.3 Hz, 1H, NH), 4.81 (d, J = 3.3 Hz, 1H, H-1”), 4.77 (d, J = 11.0 Hz, 1H, 
CH2-Ph), 4.73 (d, J = 12.5 Hz, 1H, CH2-Ph), 4.68 (d, J = 12.0 Hz, 1H, CH2-Ph), 4.64 (d, J = 
11.6 Hz, 1H, CH2-Ph), 4.58-4.42 (m, 7H, CH2-Ph, NH-CH2, H-4”), 4.40 (d, J = 11.8 Hz, 1H, 
CH2-Ph), 4.37 (d, J = 11.6 Hz, 1H, CH2- Ph), 4.20 (d, J = 0.8 Hz, 1H, H-5”), 4.18-4.12 (m, 
1H, H-2), 3.95 (dd, J = 3.4 Hz and 10.0 Hz, 1H, H-2”), 3.87 (dd, J = 2.6 Hz and 10.0 Hz, 1H, 
H-3”), 3.75-3.63 (m, 3H, H-1 and H-3), 3.48-3.40 (m, 1H, H-4), 1.88-1.69 (m, 2H, COCH2), 
1.58-1.07 (m, 72H, CH2), 0.81 (t, J = 6.7 Hz, 6H, CH3).  
13C NMR (75 MHz, CDCl3): δ 173.02, 168.56, 140.27, 138.77, 138.76, 138.54, 138.52, 
128.65, 128.63, 128.62, 128.39, 128.33, 128.19, 128.07, 128.01, 127.90, 127.88, 127.77, 
127.69, 127.12, 126.52, 125.44, 99.06, 79.96, 79.01, 78.57, 77.70, 77.28, 76.86, 76.23, 76.03, 
75.61, 74.05, 73.45, 72.58, 72.02, 71.89, 68.21, 50.10, 38.03, 36.90, 32.18, 32.17, 30.29, 
30.08, 29.98, 29.96, 29.93, 29.91, 29.86, 29.70, 29.63, 29.61, 26.15, 25.88, 22.95, 14.38.  
Exact mass (ESI-MS) for C90H132N2O9S [M+H]+ found, 1417.9757; calcd, 1417.9732 
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(2S,3S,4R)-(2,3,4-tri-O-benzyl-N-(naphthalen-1-ylmethyl)-α-D-
galactopyranuronamidyl)-3,4-di-O-benzyl-2-(hexacosanamido)octadecane-3,4-diol (11g)  
1H NMR (300 MHz, CDCl3): δ 7.98 (d, J = 8.2 Hz, 1H, arom. H), 7.85 (d, J = 7.8 Hz, 1H, 
arom. H), 7.77 (d, J = 8.2 Hz, 1H, arom. H), 7.50-7.23 (m, 29H, arom. H), 6.85 (t, J = 5.6 Hz, 
1H, NH), 5.78 (d, J = 8.4 Hz, 1H, NH), 4.92-4.36 (m, 15H, H-1”, CH2-Ph, NH-CH2, H-4”, H-
5”), 4.28-4.20 (m, 1H, H-2), 4.04 (dd, J = 3.2 Hz and 10.0 Hz, 1H, H-2”), 3.98 (dd, J = 2.0 Hz 
and 10.0 Hz, 1H, H-3”), 3.82-3.69 (m, 3H, H-1 and H-3), 3.53-3.47 (m, 1H, H-4), 1.97-1.79 
(m, 2H, COCH2), 1.62-1.18 (m, 72H, CH2), 0.90 (t, J = 6.5 Hz, 6H, CH3) 
13C NMR (75 MHz, CDCl3): δ 173.05, 168.73, 138.84, 138.75, 138.73, 138.53, 138.50, 
134.02, 133.14, 131.56, 128.98, 128.95, 128.69, 128.65, 128.60, 128.43, 128.28, 128.18, 
128.08, 127.98, 127.88, 127.84, 127.77, 127.71, 126.84, 126.51, 126.15, 125.67, 123.50, 
99.02, 79.94, 78.89, 78.59, 77.71, 77.29, 76.86, 76.30, 76.06, 75.61, 74.06, 73.47, 72.59, 
72.00, 71.95, 68.20, 50.07, 41.30, 36.88, 32.18, 30.22, 30.08, 29.99, 29.96, 29.91, 29.87, 
29.71, 29.64, 29.62, 26.15, 25.89, 22.95, 14.39.  
Exact mass (ESI-MS) for C96H136N2O9 [M+H]+ found, 1462.0370; calcd, 1462.0324 
General procedure for debenzylation: (5a-5c and 6a-6e). 
A solution of the protected amide/carbamate (0.03 mmol) in CHCl3 (0.4 mL) and EtOH (1.2 
mL) was hydrogenated under atmospheric pressure in the presence of palladium black (10 
mg). Upon reaction completion, the mixture was diluted with pyridine and filtered through 
celite. The filter cake was rinsed with CHCl3 and EtOH and the filtrate was evaporated to 
dryness. After purification by column chromatography (DCM/MeOH), final compounds 5a 
(81%), 5b (68%), 5c (86%), 6a (86%), 6b (63%), 6c (49%), 6d (80%) and 6e (79%) were 
afforded as white powders.  
17 
 
(2S,3S,4R)-1-O-(6-O-(4-chlorophenylcarbamoyl)-α-D-galactopyranosyl)-2-
(hexacosanamido)octadecane-1,3,4-triol (5a)  
1H NMR (300 MHz, pyridine-d5): δ 10.73 (s, 1H, NH), 8.58 (d, J = 8.2 Hz, 1H, NH), 7.91 (d, 
J = 8.7 Hz, 2H, arom. H), 7.40 (d, J = 8.9 Hz, 2H, arom. H), 6.99 (br. s, 1H, OH), 6.75 (br. s, 
1H, OH), 6.62 (d, J = 3.7 Hz, 1H, OH), 6.45 (d, J = 6.6 Hz, 1H, OH), 6.27 (d, J = 6.8 Hz, 1H, 
OH), 5.51 (d, J = 3.9 Hz, 1H, H-1”), 5.21-5.18 (m, 1H, H-2), 5.03 (dd, J = 8.1 and 11.0 Hz, 
1H, H-6”), 4.79 (dd, J = 3.5 Hz and 11.0 Hz, 1H, H-6”), 4.66-4.57 (m, 3H, H-1, H-2”, H-5”), 
4.39-4.24 (m, 5H, H-3”, H-4”, H-1, H-3, H-4), 2.46 (t, J = 7.5 Hz, 2H, COCH2), 1.98-1.18 
(m, 72H, CH2), 0.88 (t, J = 6.3 Hz, 6H, CH3).  
13C NMR (75 MHz, pyridine-d5): δ 172.33, 153.39, 138.14, 128.14, 128.05, 126.14, 119.21, 
100.24, 74.89, 71.53, 70.08, 69.72, 69.27, 68.86, 67.57, 64.78, 50.50, 35.64, 32.88, 30.96, 
30.94, 29.31, 29.18, 28.98, 28.87, 28.84, 28.76, 28.74, 28.70, 28.63, 28.57, 28.45, 28.43, 
25.37, 25.18, 21.77, 13.11.  
Exact mass (ESI-MS) for C57H103ClN2O10 [M+H]+ found, 1011.7393; calcd, 1011.7374; m.p. 
162.0°C – 164.0°C. 
(2S,3S,4R)-1-O-(6-O-(1-naphthylcarbamoyl)-α-D-galactopyranosyl)-2-
(hexacosanamido)octadecane-1,3,4-triol (5b)  
1H NMR (300 MHz, pyridine-d5): δ 10.68 (s, 1H, NH), 8.74-8.70 (m, 1H, arom H), 8.58 (d, J 
= 8.6 Hz, 1H, NH), 8.26 (d, J = 7.3 Hz, 1H, arom. H), 7.94 (d, J = 7.5 Hz, 1H, arom. H), 7.74 
(d, J = 8.4 Hz, 1H, arom. H), 7.62-7.51 (m, 3H, arom. H), 5.58 (d, J = 3.9 Hz, 1H, H- 1”), 
5.28-5.22 (m, 1H, H-2), 5.17-5.06 (m, 1H, H-6”), 4.94 (dd, J = 4.2 Hz and 11.2 Hz, 1H, H-
6”), 4.84-4.65 (m, 3H, H-1, H-5”, H-2”), 4.48-4.37 (m, 4H, H-1, H-3, H-3”, H-4”), 4.33-4.28 
(m, 1H, H-4), 2.51-2.46 (m, 2H, COCH2), 1.93-1.23 (m, 72H, CH2), 0.91-0.86 (m, 6H, CH3).  
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13C NMR (75 MHz, pyridine-d5): δ 172.27, 154.65, 149.43, 135.00, 133.63, 127.56, 125.15, 
125.11, 125.04, 123.71, 100.24, 75.11, 71.50, 70.10, 69.75, 69.29, 68.90, 64.83, 50.45, 35.66, 
30.95, 30.94, 29.19, 28.95, 28.86, 28.83, 28.76, 28.74, 28.68, 28.62, 28.58, 28.45, 28.43, 
25.32, 25.22, 21.76, 13.10.  
Exact mass (ESI-MS) for C61H106N2O10 [M+H]+ found, 1027.7919; calcd, 1027.7926; m.p. 
159.0 °C–161.0 °C. 
(2S,3S,4R)-1-O-(6-O-(4-pyridinylcarbamoyl)-α-D-galactopyranosyl)-2-
(hexacosanamido)octadecane-1,3,4-triol (5c)  
1H NMR (300 MHz, pyridine-d5): δ 11.18 (s, 1H, NH), 8.83 (d, J = 8.3 Hz, 1H, NH), 8.67 
(dd, J = 1.4 Hz and 4.8 Hz, 2H, arom. H), 7.93 (dd, J = 1.4 Hz and 4.8 Hz, 2H, arom. H), 5.55 
(d, J = 3.8 Hz, 1H, H-1”), 5.26-5.20 (m, 1H, H-2), 5.08 (dd, J = 8.2 Hz and 11.0 Hz, 1H, H- 
6”), 4.77 (dd, J = 3.4 Hz and 11.0 Hz, 1H, H-6”), 4.72- 4.62 (m, 3H, H-1, H-2”, H-5”), 4.45-
4.30 (m, 5H, H-3”, H-4”, H-1, H-3, H-4), 2.53 (t, J = 7.5 Hz, 2H, COCH2), 1.95-1.23 (m, 
72H, CH2), 0.88 (t, J = 6.5 Hz, 6H, CH3).  
13C NMR (75 MHz, pyridine-d5): δ 173.94, 154.68, 151.19, 147.76, 113.56, 101.56, 76.57, 
72.96, 71.66, 70.43, 53.40, 46.06, 37.19, 32.45, 30.72, 30.50, 30.38, 30.34, 30.27, 30.24, 
30.17, 30.09, 29.94, 26.89, 26.75, 23.26, 14.61.  
Exact mass (ESI-MS) for C56H103N3O10 [M+H]+ found, 978.7662; calcd, 978.7722; m.p. 
decomposition. 
(2S,3S,4R)-(N-phenyl-α-D-galactopyranuronamidyl)-2-(hexacosanamido)octadecane-3,4-
diol (6a)  
1H NMR (300 MHz, pyridine-d5): δ 9.88 (s, 1H, NH), 8.49 (d, J = 8.8 Hz, 1H, NH), 8.12 (dd, 
J = 1.1 Hz and 8.6 Hz, 2H, arom. H), 7.36-7.30 (m, 3H, arom. H and OH), 7.10 (t, J = 7.3 Hz, 
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1H, arom. H), 6.79 (d, J = 5.2 Hz, 1H, OH), 6.43 (d, J = 5.9 Hz, 1H, OH), 6.12 (d, J = 5.4 Hz, 
1H, OH), 5.47 (d, J = 3.8 Hz, 1H, H-1”), 5.27- 5.24 (m, 1H, H-2), 5.02-4.99 (m, 3H, OH, H-
4” and H-5”), 4.66-4.55 (m, 2H, H-1 and H-2”), 4.44 (app. d, J = 9.2 Hz, 1H, H-3”), 4.32-
4.21 (m, 3H, H-1, H-3, H-4), 2.49-2.44 (m, 2H, COCH2), 1.40-1.12 (m, 72H, CH2), 0.88 (t, J 
= 6.6 Hz, 6H, CH3).  
13C NMR (75 MHz, pyridine-d5): δ 173.77, 169.23, 139.70, 129.36, 120.95, 101.60, 76.53, 
74.21, 72.76, 71.71, 71.36, 69.97, 69.18, 51.49, 37.07, 34.44, 32.44, 32.43, 30.67, 30.45, 
30.35, 30.31, 30.24, 30.22, 30.19, 30.11, 30.07, 29.93, 29.91, 26.80, 26.71, 23.25, 14.60.  
Exact mass (ESI-MS) for C56H102N2O9 [M+H]+ found, 947.7612; calcd, 947.7658;  m.p. 
136.0 °C–138.0 °C. 
(2S,3S,4R)-(N-(3,4-dichlorophenyl)-α-D-galactopyranuronamidyl)-2-
(hexacosanamido)octadecane-3,4-diol (6b)  
1H NMR (300 MHz, pyridine-d5): δ 10.19 (s, 1H, NH), 8.52 (d, J = 8.7 Hz, 1H, NH), 8.46 (d, 
J = 2.4 Hz, 1H, arom. H), 7.92 (dd, J = 2.4 Hz and 9.0 Hz, 1H, arom. H), 7.39 (d, J = 9.0 Hz, 
1H, arom. H), 7.28 (bs, 1H, OH), 6.85 (bs, 1H, OH), 6.45 (d, J = 4.2 Hz, 1H, OH), 6.13 (bs, 
1H, OH), 5.40 (d, J = 3.6 Hz, 1H, H-1”), 5.27-5.23 (m, 1H, H-2), 5.03-4.96 (m, 3H, H-4”, H-
5” and OH), 4.62 (dd, J = 3.6 Hz and 10.5 Hz, 1H, H-2”), 4.57 (dd, J = 5.1 Hz and 10.8 Hz, 
1H, H-3), 4.44 (dd, J = 1.8 Hz and 9.6 Hz, 1H, H-3”), 4.26-4.21 (m, 3H, H-1 and H-4), 2.49-
2.44 (m, 2H, COCH2), 2.29-1.18 (m, 72H, CH2), 0.89 (t, J = 6.6 Hz, 6H, CH3).  
13C NMR (75 MHz, pyridine-d5): δ 171.94, 168.21, 138.12, 131.03, 129.39, 125.19, 121.60, 
121.10, 119.06, 100.22, 75.33, 72.80, 71.31, 70.27, 68.78, 68.42, 49.86, 35.56, 33.15, 30.95, 
30.94, 29.17, 28.95, 28.86, 28.83, 28.76, 28.74, 28.70, 28.64, 28.58, 28.45, 28.43, 25.29, 
25.21, 21.76, 13.10.  
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Exact mass (ESI-MS) for C56H100Cl2N2O9 [M+Na]+ found, 1015.6865; calcd, 1015.6884; 
m.p. 155.0 °C – 157.0 °C. 
(2S,3S,4R)-(N-benzyl-α-D-galactopyranuronamidyl)-2-(hexacosanamido)octadecane-3,4-
diol (6c)  
1H NMR (300 MHz, pyridine-d5): δ 8.69 (dd, J = 5.9 Hz and 6.8 Hz, 1H, NH), 8.47 (d, J = 
8.7 Hz, 1H, NH), 7.59 (d, J = 5.9 Hz, 2H, arom. H), 7.30-7.17 (m, 4H, arom. H and OH), 6.40 
(bs, 1H, OH), 5.58 (d, J = 3.9 Hz, 1H, H- 1”), 5.03-5.00 (m, 2H, H-2 and OH), 4.98-4.95 (m, 
4H, H-4”, OH and NH-CH2), 4.69 (dd, J = 3.8 Hz and 9.9 Hz, 1H, H-2”), 4.63-4.56 (m, 2H, 
H-3 and H-5”), 4.44 (dd, J = 3.1 Hz and 10.0 Hz, 1H, H- 3”), 4.34-4.27 (m, 3H, H-1 and H-
4), 2.48-2.43 (m, 2H, COCH2), 1.93-1.09 (m, 72H, CH2), 0.89 (t, J = 6.7 Hz, 6H, CH3).  
13C NMR (75 MHz, pyridine-d5): δ 172.12, 169.18, 138.92, 127.50, 126.55, 125.87, 123.04, 
121.66, 100.15, 75.12, 72.52, 71.26, 70.08, 69.96, 68.61, 67.55, 49.94, 41.71, 35.57, 32.98, 
30.96, 30.94, 29.20, 28.98, 28.87, 28.83, 28.76, 28.74, 28.70, 28.63, 28.58, 28.45, 28.43, 
25.32, 25.22, 21.77, 13.11.  
Exact mass (ESI-MS) for C57H104N2O9 [M+H]+ found, 961.7808; calcd, 961.7815; m.p. 
128.0 °C – 130.0 °C. 
(2S,3S,4R)-(N-(3,4-dichlorobenzyl)-α-D-galactopyranuronamidyl)-2-
(hexacosanamido)octadecane-3,4-diol (6d)  
1H NMR (300 MHz, pyridine-d5): δ 8.96 (dd, J = 5.7 Hz and 7.1 Hz, 1H, NH), 8.48 (d, J = 
8.6 Hz, 1H, NH), 7.77 (d, J = 1.9 Hz, 1H, arom. H), 7.41 (dd, J = 2.0 Hz and 8.3 Hz, 1H, 
arom. H), 7.32 (d, J = 8.2 Hz, 1H, arom. H), 6.75 (app. s, 1H, OH), 6.43 (d, J = 5.7 Hz, 1H, 
OH), 6.13 (d, J = 4.8 Hz, 1H, OH), 5.60 (d, J = 3.8 Hz, 1H, H-1”), 5.26 (app. d, J = 4.6 Hz, 
1H, H-2), 5.01-4.92 (m, 3H, NH-CH2, H-4” and H-5”), 4.69-4.56 (m, H2, H-2” and H-1), 
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4.49-4.42 (m, 2H, H-3” and NH-CH2), 4.33-4.29 (m, 3H, H-1, H-3 and H- 4), 2.46 (app. t, J = 
7.5 Hz, 2H, COCH2), 1.97-1.16 (m, 72H, CH2), 0.89 (t, J = 6.7 Hz, 6H, CH3).  
13C NMR (75 MHz, pyridine-d5): δ 173.43, 170.90, 141.50, 132.57, 130.84, 130.65, 130.10, 
127.77, 101.72, 76.86, 74.10, 72.75, 71.68, 71.44, 70.08, 51.32, 42.16, 37.07, 34.66, 32.45, 
32.46, 30.71, 30.48, 30.38, 30.34, 30.27, 30.25, 30.20, 30.14, 30.10, 29.96, 29.94, 26.80, 
26.72, 23.28, 14.61.  
Exact mass (ESI-MS) for C57H102Cl2N2O9 [M+H]+ found, 1029.7021; calcd, 1029.7041; 
m.p. 144.0 °C – 146.0 °C. 
(2S,3S,4R)-(N-phenethyl-α-D-galactopyranuronamidyl)-2-(hexacosanamido)octadecane-
3,4-diol (6e)  
1H NMR (300 MHz, pyridine-d5): δ 8.50 (d, J = 8.7 Hz, 1H, NH), 8.13 (t, J = 6.0 Hz, 1H, 
NH), 7.32-7.18 (m, 5H, arom. H), 7.03 (br. s, 1H, OH), 6.41 (br. s, 1H, OH), 6.13 (br. s, 1H, 
OH), 5.54 (d, J = 3.9 Hz, 1H, H-1”), 5.27 (app. d, J = 4.4 Hz, 1H, H-2), 4.99-4.91 (m, 2H, H-
4” and H-5”), 4.65 (dd, J = 3.8 Hz and 10.0 Hz, 1H, H-2”), 4.60 (dd, J = 5.4 Hz and 10.7 Hz, 
1H, H-1), 4.41 (dd, J = 3.1 Hz and 10.0 Hz, 1H, H-3”), 4.39-4.31 (m, 1H, H-4), 4.30 (dd, J = 
4.2 Hz and 10.7 Hz, 1H, H-1), 3.72 (dd, J = 6.5 Hz and 14.4 Hz, 2H, NH-CH2), 2.94 (app. t, J 
= 7.5 Hz, 2H, CH2), 2.48 (t, J = 7.1 Hz, 2H, COCH2), 1.97-1.18 (m, 72H, CH2), 0.89 (t, J = 
6.6 Hz, 6H, CH3).  
13C NMR (75 MHz, pyridine-d5): δ 173.42, 170.26, 140.50, 136.52, 129.67, 129.16, 126.87, 
123.50, 101.65, 76.91, 73.90, 72.78, 71.53, 71.49, 70.11, 69.17, 51.29, 41.44, 37.08, 36.72, 
34.66, 32.46, 32.45, 30.71, 30.48, 30.37, 30.34, 30.27, 30.25, 30.21, 30.15, 30.11, 29.96, 
29.94, 26.81, 26.73, 23.27, 14.61.  
Exact mass (ESI-MS) for C58H106N2O9 [M+H]+ found, 975.7974; calcd, 975.7977; m.p. 
144.0 °C – 146.0 °C. 
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Procedure for debenzylation of 6f and 6g  
To a solution of the protected amide (0.07 mmol) in CH2Cl2 (1 mL) was added aluminum 
chloride (109 mg, 0.82 mmol) and dimethylaniline (0.13 mL, 1.00 mmol). After stirring for 8 
hours, the reaction mixture was quenched with a 1N solution of HCl (1.5 mL) followed by 
extraction with EtOAc. Next, the combined organic layers were washed with a saturated 
NaHCO3 solution and brine, dried over Na2SO4 and evaporated to dryness. The resulting 
residue was submitted to column chromatography (CH2Cl2/MeOH: 28/2), yielding amides 6f 
(10 mg, 15 %) and 6g (8.5 mg, 11 %).  
(2S,3S,4R)-(N-(thiophen-3-ylmethyl)-α-D-galactopyranuronamidyl)-2-
(hexacosanamido)octadecane-3,4-diol (6f)  
1H NMR (300 MHz, pyridine-d5): δ 8.86 (t, J = 6.2 Hz, 1H, NH), 8.45 (d, J = 8.5 Hz, 1H, 
NH), 7.25 (app. dd, J = 1.2 Hz and 5.2 Hz, 2H, arom. H), 7.11 (br. s, 1H, OH), 6.91 (dd, J = 
3.6 Hz and 5.1 Hz, 1H, arom. H), 6.68 (br. s, 1H, OH), 6.39 (br. s, 1H OH), 6.12 (br. s, 1H, 
OH), 5.55 (d, J = 3.8 Hz, 1H, H-1”), 5.28-5.21 (m, 1H, H-2), 5.0-4.82 (m, 4H, NH-CH2, H-4” 
and H-5”), 4.66 (dd, J = 3.8 Hz and 9.9 Hz, 1H, H-2”), 4.56 (dd, J = 5.4 Hz and 10.5 Hz, 1H, 
H-1), 4.41 (d, J = 3.2 Hz and 9.9 Hz, 1H, H-3”), 4.35-4.19 (m, 2H, H-3 and H-4), 4.25 (dd, J 
= 4.2 Hz and 10.6 Hz, 1H, H-1), 2.44 (app. t, J = 7.4 Hz, 2H, COCH2), 1.92-1.19 (m, 72H, 
CH2), 0.89 (t, J = 6.7 Hz, 6H, CH3).  
13C NMR (75 MHz, pyridine-d5): δ 171.87, 168.91, 141.99, 125.87, 124.66, 123.74, 100.23, 
75.37, 72.51, 71.25, 70.01, 69.97, 68.60, 67.72, 53.86, 49.76, 36.91, 35.55, 33.13, 30.95, 
30.94, 29.20, 28.97, 28.87, 28.83, 28.75, 28.74, 28.69, 28.63, 28.58, 28.45, 28.43, 25.29, 
25.20, 21.76, 13.10.  
Exact mass (ESI-MS) for C55H102N2O9S [M+H]+ found, 967.7431; calcd, 967.7379; m.p. 
126.0°C – 128.0°C. 
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(2S,3S,4R)-(N-(naphtalen-1-ylmethyl)-α-D-galactopyranuronamidyl)-2-
(hexacosanamido)octadecane-3,4-diol (6g)  
1H NMR (300 MHz, pyridine-d5): δ 8.49 (d, J = 8.7 Hz, 1H, NH), 8.29 (dd, J = 2.7 Hz and 
6.7 Hz, 1H, NH), 7.94 (d, J = 7.2 Hz, 1H, arom. H), 7.87 (dd, J = 3.1 Hz and 6.3 Hz, 1H, 
arom. H), 7.77 (d, J = 8.3 Hz, 1H, arom. H), 7.59-7.38 (m, 4H, arom. H), 5.54 (d, J = 3.7 Hz, 
1H, H- 1”), 5.44 (dd, J = 6.7 Hz and 15.6 Hz, 1H, NH-CH2), 5.29-5.21 (m, 1H, H-2), 5.13-
4.95 (m, 3H, NH-CH2, H- 4” and H-5”), 4.68 (dd, J = 3.7 Hz and 9.8 Hz, 1H, H- 2”), 4.60 
(dd, J = 5.4 Hz and 10.6 Hz, 1H, H-1), 4.45 (dd, J = 3.1 Hz and 10.0 Hz, H-3”), 4.43-4.29 (m, 
2H, H-3 and H-4), 4.28 (dd, J = 4.4 Hz and 10.7 Hz, 1H, H-1), 2.46 (app. t, J = 7.1 Hz, 2H, 
COCH2), 1.97-1.19 (m, 72H, CH2), 0.89 (t, J = 6.6 Hz, 6H, CH3).  
13C NMR (75 MHz, pyridine-d5): δ 173.42, 170.60, 134.50, 132.12, 129.31, 128.21, 126.85, 
126.35, 126.27, 125.92, 101.77, 76.84, 74.18, 72.79, 71.63, 71.50, 70.12, 69.29, 55.37, 51.34, 
41.33, 37.07, 34.62, 32.47, 30.82, 30.71, 30.48, 30.38, 30.34, 30.27, 30.25, 30.21, 30.15, 
30.11, 29.96, 29.94, 26.81, 26.73, 23.28, 14.62.  
Exact mass (ESI-MS) for C61H106N2O9 [M+H]+ found, 1011.7974; calcd, 1011.7971; m.p. 
121.0 °C – 123.0 °C. 
Biological evaluation 
Mice 
C57BL/6 and mice were in house bred (in accordance with the general recommendations for 
animal breeding and housing) or purchased from the Harlan Laboratory,. Experiments were 
conducted according to the guidelines of the Ethical Committee of Laboratory Animals 
Welfare of Ghent University.  Mice used for experiments were between 5 and 12 weeks old.  
In vivo activation of iNKT cells and serum analysis 
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For in vivo activation of iNKT cells C57BL/6 mice were intraperitoneally injected with 5 µg 
glycolipid (dissolved in PBS with DMSO). Subsequently mice were bled at 4hours and 16 
hours after injection.  Serum was stored at -20 and analyzed for IL-4 and IFN-γ levels by 
ELISA. 
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